Jonathan Sporn

Jonathan is the CEO and founder of Gilgamesh Pharmaceuticals. Prior to Gilgamesh – a platform company developing an oral arylcyclohexylamine & the next generation of psychedelic-related medicines with novel benefits, improved safety profiles, and strong IP – Jonathan spent time as a Harvard and NIH Scientist, drug developer in neurology and psychiatry at J&J and Pfizer, Sr Director in R&D and Business Development (Lyrica, Pristiq), sole founder of Perception Neuroscience that exited to ATAI, and inventor of solriamfetol (Sunosi®) and R-ketamine for substance use disorders (patent filed)